1. European Association for Vision and Eye Research – Crete, Oct 5-8, 2011 Ranibizumab for the Treatment of Exudative Age-Related Macular Degeneration Associated With Retinal Pigment Epithelial Detachment

2. Financial Disclosure  Dr Olesya Ziyatdinova (the presenter) has no financial interest in the subject matter of this topic

3. Purpose To evaluate the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment. Materials and methods The study included 15 patients (15 eyes) with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.

4. 5 eyes with foveal involvement 10 eyes without foveal involvement

5.  Duration of disease: from 3 to 12 months  Observation time: 12 months  Number of injections: from 1 to 6 times

6. Technique  Injection of 0,5 mg (0,05ml) of ranibizumab into vitreous body  Lower quadrant at a distance of 4 mm from limbus, needle 30G  Slow introduction  IOP control and instillation of antibiotics after operation

7. Technique

8. Criteria of efficacy Visual acuity (BCVA, UCVA) Ophthalmoscopy OCT

9. Results Average BCVA increased from 20/100 to 20/50 and the average retinal thickness decreased from 367 +/-111 mkm to 281+/- 104 mkm in 8 eyes (53,4%) without foveal involvement.

10. BCVA remained stable in 5 eyes (33,3%) but there was a decrease only in 2 eyes (13,3%) with foveal involvement. 3 eyes (20%) showed disease stabilization after 1 st injection 12 eyes (80%) required re-injection of the ranibizumab for 1-2 months Results

11. Before 1 month later 3 months later OCT dynamics

12. Conclusions  Intravitreal ranibizumab was effective in improving or stabilizing vision of patients with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.  The functional results were better in eyes without foveal involvement with retinal pigment epithelial detachment.  Visual acuity and OCT data are reliable criteria for evaluating the efficacy of intravitreal ranibizumab in eyes with exudative age-related macular degeneration associated with retinal pigment epithelial detachment.